Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.* 無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the "Company" or "WuXi AppTec") on a voluntary basis.

WuXi AppTec is aware of the letter dated February 12, 2024 from certain U.S. lawmakers to the Departments of Commerce, Treasury and Defense about our company. The Company has always welcomed regulatory oversight of our industry, and our company has successfully completed U.S. government reviews in the past. But the Company strongly objects to misleading allegations, inaccurate assertions and preemptive actions against our company without due process.

The Company strongly believes that WuXi AppTec <u>HAS NOT posed</u>, <u>DOES NOT pose and WILL NOT pose</u> a national security risk to the United States, and that another review of our company by U.S. government would reach the same conclusion. In fact, WuXi AppTec serves as a valued contributor to the global pharmaceutical and life sciences industries.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, February 13, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.